Abcellera Biologics is trading 4.2% down now at $9.35 after announcing a proposed $200 million underwritten offering of common shares and pre-funded warrants.
- Proceeds are intended to fund ABCL635’s continued development, pipeline research, and working capital.
- New equity supply is pressuring shares after their sharp rally following positive Phase 2 results.
- The offering was announced August 11, 2026.